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trials’ data were retrieved from the Haute Autorité de Santé (HAS) website and the 
Number Needed to Treat (NNT) to prevent one event (progression, death) was esti-
mated. An Absolute Loss of Chance (ALOC) index was calculated over the time-lag 
period and per time unit combining NNT and HAS target population size. Drugs 
with level 5 Added Medical Value (ASMR, Amélioration du Service Médical Rendu) 
were excluded. Results: Twelve drugs were granted a EUMA for solid tumours in 
2012 and 2013 with level 2-4 Added Medical Value: one drug of level 2-important 
(trastuzumab emtansine), five drugs of level 3-moderate (cabazitaxel, vemurafenib, 
critzotinib, pertuzumab, and enzalutamide), and six drugs of level 4-minor (eribu-
line, ipilimumab, abiraterone, vandetanib, axitinib, and vismodegib). The time-lags 
between EUMA and FPRD ranged from 7.4 months (enzatulamide) to 29.9 months 
(cabazitaxel). Concurrently, the overall ALOC ranged from 9 to 799 medical events 
which might have not been prevented unless alternative access (Compassionate, 
Clinical Trials), depending on drug, indication and time-lag. ConClusions: Early 
patient access for innovative drugs in oncology might help preventing a substantial 
number of progressions and deaths. ALOC might support patient access decision 
making process.
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objeCtives: The aim of this study was to assess the burden of hospitalizations for 
metastatic renal cell carcinoma (mRCC) from 2008 to 2013 in France. Methods: A 
retrospective analysis was performed using the French national hospital database 
(PMSI). Hospital stays for mRCC between 2008 and 2013 were identified by combining 
the International Classification of Diseases-10threvision (ICD-10) codes for renal cell 
carcinoma (C64) and codes for metastasis (C77 or C78 or C79). Among hospital stays, 
incident cases were selected and followed for at least 1 year. Descriptive analyses 
were performed with a focus on hospital stays and patient characteristics. Results: 
Overall, 26 124 adult patients (median age at diagnosis 71 years [18-102] years); 
67.8 % male) were hospitalized for mRCC, corresponding to 123 385 hospital stays 
mainly in public settings (80.1%). Among those patients, 13 517 (51.7 %) had lung 
metastasis, 10 149 (38.8%) had bone and bone marrow metastasis, 7 553 (28.9%) 
had liver metastasis and 3 538 (13.5%) had brain metastasis. The number of new 
cases per year was stable while the number of hospitalizations increased 37.4% 
from 2008 to 2013. Death in a hospital setting was reported for 4 443 (17%) patients. 
During the study period, there were 36 205 (29.3%) hospital stays for chemotherapy 
and immunotherapy, 9 400 (7.6%) hospital stays for radiotherapy and 5 956 (4.8%) 
hospital stays for palliative care. The mean length of stay at diagnosis was 10.1 (SD: 
13.9) vs. 4.4 (SD: 9.3) days for subsequent stays. ConClusions: To our knowledge 
this is the first study to provide an overview of the burden of mRCC in French hos-
pitals between 2008 and 2013 and constitutes the preliminary step in assessing the 
economic burden of hospitalizations for mRCC.
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objeCtives: The aim of this study was to describe the burden of metastatic mela-
noma in public and private hospitals between 2008 and 2013 in France. Methods: 
The French national hospital database (PMSI) was analyzed to identify adults 
newly diagnosed with metastatic melanoma between 2008 and 2013. Using the 
International Classification of Diseases 10threvision codes for melanoma (C43) and 
for metastasis (C77 or C78 or C79), the number of hospital admissions for metastatic 
melanoma was identified and thereafter the corresponding number of hospitalized 
patients was determined. Descriptive analyses were performed with a focus on 
hospital stays and patient characteristics. Results: Between 2008 and 2013, 16 188 
patients (median age at diagnosis 66 years [18 -103]; 54.6 % male) were hospitalized 
for metastatic melanoma, corresponding to 104 731 hospital admissions mainly in 
public settings (94.8%). We identified 27 523 (26.3%) hospital admissions for chemo-
therapy and immunotherapy and only 2 943 (2.8%) hospital admissions for pallia-
tive care. 24.0% of diagnosis related groups were classified as surgery procedures. 
Hospital admissions were mainly performed in three regions: Ile-de-France (18.6%), 
Rhône Alpes (13.1%) and Aquitaine (12.6%). The mean length of stay was 3.2 days (SD: 
7.1). 39.8% of patients had 1 site of metastasis, 18.0% had 2 sites of metastasis and 
42.1% had at least 3 sites of metastasis. The most common sites of metastasis were 
lung in 36.8% of patients, liver in 28.8% of patients and brain in 27.8% of patients. 
Death in a hospital setting was reported for 10.3% of patients. ConClusions: This 
analysis allows us to strengthen our knowledge regarding the burden of metastatic 
melanoma which represents a first step in assessing the cost of hospitalizations 
related to metastatic melanoma. Such analysis is useful for economic modeling 
especially with the arrival of innovative treatments.
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objeCtives: There is an acute problem concerning lymphoma treatment in 
Ukraine. Previously, due to unavailability of up-to-date chemotherapy (CT) regimes, 
only 20% of lymphoma patients had a chance for persistent remission after the 
treatment, 40-60% of patients had response to treatment and only 35% of patients 
had 5-year survival rates. Todays clinical protocols of therapy in lymphoma patients 
take into account world’s experience. Methods: Clinical Practice Guidelines for the 
Diagnosis and Management of Lymphoma. A National Health and Medical Research 
illomavirus vaccine acceptance in Asian populations. Methods: Students studying 
undergraduate health professional courses (Medicine, Dentistry, Pharmacy, Nursing) 
in a private medical University in Kuala Lumpur, Malaysia in the period from June 
2014 - January 2015 were selected. The participants’ demographic details were gath-
ered by a self-administered questionnaire. The contingent valuation method was 
used to assess each respondent’s willingness to pay to take HPV vaccination and 
reduce the risk of cervical cancer. This method represents a single “take it or leave it 
offer”, whereby people are asked if they are willing to pay a specific pre-determined 
price for the benefit presented. Results: The mean age of the respondents was 23.5 
years, (SD ±1. 0). 55.2% reported as being in a relationship. Most of the participants 
were willing to pay an amount up to RM 500 to receive HPV vaccination. The median 
WTP for HPV vaccination is RM 465. Age, gender, and the patient’s perceived health 
status at baseline were not associated with WTP. Respondents who are in a relation-
ship (committed and dating) showed greater interest in vaccinating themselves and 
the relationship status emerged as unique predictors; Committed (OR= 2.20, P < 0.05) 
and dating (OR = 2.20, P< 0. 05). ConClusions: Avoidance of human papillomavirus 
infection and cervical cancer may have considerable value to the undergraduate 
students of health professional courses and this data will help future validation in 
a larger population in Malaysia.
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objeCtives: High cost and highly effective cancer treatment are changing the 
survivorship landscape with implications for pharma, payers and patients. High 
initial cost of care may be mitigated by lower global cost of care and significantly 
lower subsequent year cost. However, such long term value may be lost if patients 
switch coverage at general market frequency. We compared published benchmark 
coverage switch data to a breast cancer and non-cancer cohort to evaluate if patients 
with a cancer diagnosis are less likely to switch coverage. Methods: Breast cancer 
patients and a control group of non-cancer patients were identified using data 
obtained from the Cardinal Health Specialty Solutions Revenue Cycle Management 
(RCM) medical claims database. Patients had a claim during the 12 month period 
ending April 2014, were 60 years old or younger, diagnosed as of 2011 or later, and 
had at least 3 years of follow-up data available. Payer information at index period 
and at time of switch was recorded and insurance patterns examined. Data was ana-
lyzed using a chi-square test and Kaplan-Meier graphs. Results: There were 1440 
patients with breast cancer and 3950 patients with non-cancer diagnoses in the final 
study sample. Breast cancer patients switched payer at a statistically lower propor-
tion than the non-cancer control group, 22.7% versus 26.0% respectively (p= 0.014). 
Time to payer switch estimated through a Kaplan-Meier analysis demonstrated 
a longer time to payer switch for breast cancer patients versus the control group 
(3.59 years versus 3.56 years, p= 0.037). ConClusions: Despite protection against 
pre-existing condition uninsurability, a lower proportion of breast cancer patients 
switched payers during the study time window and had a longer estimated time 
to payer switch. Such trends will be of interest to payers and pharma as both seek 
understanding of value based care for their respective businesses.
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objeCtives: HCV infection caused 1,2 million DALY in 2002 in Europe and 200 104 
YLDs. 1% of these YLDs resulted from HCV-related hepatocellular carcinoma. The 
objective of the present study is to calculate the DALY for patients with HCV-related 
HCC in Bulgaria. Methods: It is a retrospective real-life observational study of 445 
patients with hepatocellular carcinoma registered in the National Cancer Registry 
for 2-year period (2012-2014). Data on demographic, clinical characteristics, previ-
ous, and concomitant diseases of the liver was collected from the patient registries. 
DALYs for these patients wàs calculated based on the WHO methodology. Results: 
350 of the observed patients were diagnosed with HCC in 3rd and 4th stage and 280 
of the patients were in productive ages. The mortality rate was significantly high – 
83% for the observed period. Chronic HCV infection and cirrhosis were found to be 
leading pathology for the development of HCC as ~ 20% of the patients with HCC 
and previous/concomitant liver diseases reported chronic hepatitis C infection and 
cirrhosis. For the 445 patients were calculated 798 years life lost (YLL) and 958 years 
lived with disability (YLD). DALY accounted for 1756. ConClusions: HCV-related 
cirrhosis and HCC implicit high social burden. The high mortality rate causes huge 
productivity losses for the society.
Pcn259
a loss of chance index: a new tool for oPtiMizing Patient access to 
innoVatiVe drugs
Gavini F1, Sarkozy F2, Jouan-Flahault C3, Fumoleau P4
1ROCHE SAS - FRANCE, Boulogne Billancourt, France, 2FSNB Health & Care, Paris, France, 3LEEM, 
Paris, France, 4Centre Georges François Leclerc, Dijon, France
objeCtives: Our objectives were to report time-lags between European Marketing 
Authorisation (EUMA) and French Pricing and Reimbursement Decision (FPRD) for 
recent innovative anti-cancer drugs and to quantify the corresponding patient loss 
of chance. Methods: We included 2012-2013 EMA-approved anti-cancer drugs in 
solid tumours and calculated the time-lag between EUMA and FPRD. Official pivotal 
